CEO buys 25,350 Edwards Lifesciences shares at $59.26, signaling confidence while market sees modest decline – what it means for investors and valuation.
Edwards Lifesciences insider buy by executive Daniel Lippis signals strong confidence ahead of the JenaValve acquisition, hinting at potential upside for investors.